Stephen Liu, MD, on the Potential Treatment Impact of Amivantamab Plus Lazertinib in EGFR+ NSCLC at ASCO 2021

CancerNetwork® sat down with Stephen Liu, MD, of the Georgetown Lombardi Comprehensive Cancer Center, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about treatments for patients with EGFR–mutant lung cancer following frontline osimertinib (Tagrisso). One such combination of amivantamab (Rybrevant) with lazertinib was presented at the meeting and may have the potential impact the care of patients following disease relpase.

Transcription:

At ASCO, [we saw] a lot of new data come out. One of the abstracts I [was] excited to see was number 9006. That one is looking at amivantamab with lazertinib after osimertinib progression for patients with EGFR-mutant lung cancer. For patients with advanced EGFR-mutant lung cancer, osimertinib has been our standard of care for many years now, but the [median] progression free survival of about 1 and a half years really leaves us wanting more. And at resistance, treatment options really fall off; the mechanisms of resistance after osimertinib are very heterogeneous. This strategy of combining a [tyrosine kinase inhibitor] with by specific antibody—like amivantamab, [which is] recently approved for EGFR exon 20[–positive] non–small cell lung cancer—could really give us a more exciting option after osimertinib. I really want to see the details, where we’re seeing responses, what types of responses, and what patients [have] seen those responses. I think that that has a chance to really impact care for EGFR-mutant lung cancer.

Reference

Bauml J, Cho B, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. ASCO Meeting Library. 2021. doi: 10.1200/JCO.2021.39.15_suppl.9006